Erasca (ERAS) Non Operating Income (2020 - 2026)
Erasca posted quarterly Non Operating Income of $4.5 million for Q1 2026, up 5982.89% year-on-year from $73501.2 in Q1 2025, and down 72.99% on a QoQ basis from $16.6 million in Q4 2025.
Erasca (ERAS) has 7 years of Non Operating Income data on file, last reported at $4.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 5982.89% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $29.2 million (up 27.16% YoY), and the FY2025 full-year result was $16.4 million, down 8.8% from the prior year.
- Non Operating Income for Q1 2026 stood at $4.5 million, down from $16.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $18.3 million in Q4 2024 and bottomed at -$76000.0 in Q1 2025.
- The 5-year median for Non Operating Income is $3.9 million (2025), against an average of $4.5 million.
- The widest annual swing landed in 2023, when Non Operating Income jumped 8040.43%; it then slumped 101.98% in 2025.
- A 5-year view of Non Operating Income shows it stood at $2.8 million in 2022, then soared by 47.49% to $4.2 million in 2023, then soared by 338.5% to $18.3 million in 2024, then slipped by 9.5% to $16.6 million in 2025, then tumbled by 72.99% to $4.5 million in 2026.
- The last three Non Operating Income figures came in at $4.5 million (Q1 2026), $16.6 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | 16.55 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 4.25 Mn |
| Mar 31, 2025 | -76,000.00 |
| Dec 31, 2024 | 18.29 Mn |
| Sep 30, 2024 | 173,000.00 |
| Jun 30, 2024 | 4.58 Mn |
| Mar 31, 2024 | 3.83 Mn |
| Dec 31, 2023 | 4.17 Mn |
| Sep 30, 2023 | 4.30 Mn |
| Jun 30, 2023 | 4.19 Mn |
| Mar 31, 2023 | 3.83 Mn |
| Dec 31, 2022 | 2.83 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 297,000.00 |
| Mar 31, 2022 | 47,000.00 |
| Dec 31, 2021 | 584,000.00 |
| Sep 30, 2021 | -25,000.00 |
| Jun 30, 2021 | -30,000.00 |
| Mar 31, 2021 | 1.59 Mn |
| Dec 31, 2020 | -2.63 Mn |
| Sep 30, 2020 | 555,000.00 |
| Jun 30, 2020 | 1.79 Mn |